HCRTR1 and psychotic disorder: In conclusion, we have demonstrated that by targeting orexin receptors with the FDA-approved DORA, Suvorexant (30 mg/kg), OX1R antagonist, SB334867, and the OX1R antagonist, EMPA, we are able to restore normal dopamine system function in a rodent model of stress-induced pathophysiology relevant to PTSD and comorbid psychosis.